Exhibitors and Sponsors

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers worldwide. We use our expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives.

Our flagship product, The NGAL Test™, aids in the risk assessment of acute kidney injury (AKI) in critically ill patients. In conjunction with clinical evaluation, The NGAL Test is designed to identify levels of NGAL, a biomarker that rises rapidly in response to kidney injury, preceding changes in creatinine by as much as 2 to 3 days. Early identification of patients at risk of developing AKI allows clinicians to take more appropriate action to manage fluid levels, avoid nephrotoxic agents, and potentially prevent permanent kidney damage.

Designed to run on standard chemistry analyzers, there is no need for investment in new laboratory equipment. The NGAL Test is CE marked for IVD use in the European Union, Korea and Israel. For Research Use Only in all other regions. 

BioPorto is headquartered in Denmark, with US headquarters in Chicago, and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

See further about The NGAL Test.

Children’s Hospital & Medical Center, in affiliation with the University of Nebraska College of Medicine, is expanding to be a global leader for children’s health. Located in Omaha, Nebraska, Children’s is Nebraska’s only full-service pediatric specialty health center. Our free-standing pediatric teaching hospital includes a Level IV NICU, Level II Pediatric Trauma Center, specialized clinical pediatric services and 24/7 pediatric intensivists. Children’s has 50+ specialty clinics, 250+ pediatric specialists, 15 satellite offices, pediatric fellowship programs and is Magnet-certified. 

Focused on exceptional clinical care, education, clinical and outcomes research and advocacy, Children’s is on a journey of transformational growth to address local, regional, national and global patient care needs. Our new campus will expand several key areas, including NICU, PICU, Cardiac Care Center, Fetal Care Center, Surgical Services, education and clinical and outcomes research. 

Click here to explore our pediatric opportunities, or call Jon Clay, Physician Recruitment Administrator, at 402.955.6971. Grow with us!

Vygon UK – Demonstrating leading technology in paediatric vascular access and haemodynamic monitoring

The Cardiac Center at Children’s Hospital of Philadelphia (CHOP) has one of the largest and most accomplished teams of pediatric cardiac experts in the world. We partner with physician colleagues from across the country and the world to care for patients from before birth through adulthood. At CHOP, some of the world’s leading experts are transforming the future for children with congenital heart disease by pioneering breakthroughs in treatment that will improve the lives of patients now-and for generations to come. 

https://www.chop.edu/centers-programs/cardiac-center

Etiometry is the pioneer and leading global provider of model-based analytics software, designed for use in the critical care setting. The FDA-cleared Etiometry Platform is fast becoming the new standard for clinical decision support. The unique data aggregation, analysis, archiving, and visualization platform provides a dynamic and objective assessment of patient risk, enabling clinicians to make more confident, and informed treatment decisions for their patients. As the recipient of an innovation award, Etiometry's technology is currently utilized in leading institutions across three continents. 

Genedrive Diagnostics Ltd. is a passionate, near patient molecular diagnostics company committed to tackling the challenges presented by current global health issues. We aim to do this by providing our rapid, affordable and simple to use point of need molecular diagnostics platform for use in global health issues such as pharmacogenetics and pathogen detection.

The Genedrive® MT-RNR1 ID Kit is a rapid, portable, non-invasive DNA test used for the detection of MT-RNR1 in human buccal cells. Around 1:500 people carry the variant.
The rapid decision-making, genetic-based diagnostic test can return an actionable result within the strict timeframe required in the acute setting of a neonatal intensive care unit, allowing alternative antibiotics to be prescribed, thus avoiding the any adverse reaction to gentamicin.
Genedrive’s CE marked test will be utilised in an implementation study at two UK NICU’s to assess the impact of rapid genetic testing as a method of avoiding irreversible hearing loss in neonates treated with antibiotics.

Intersurgical is Europe’s leading designer, manufacturer and supplier of a wide range of medical devices for respiratory support.

We provide flexible patient solutions for airway management, anaesthesia, critical care, and oxygen & aerosol therapy primarily for use within the hospital environment.  

With over 30 years’ experience in this area, we understand the changing and challenging clinical environments and needs of our customers and their patients.   We believe the best way to maintain the highest standards in design, manufacture, quality and customer care is to have complete control of these aspects of our business. This integrated in-house philosophy means we are able to respond quickly and effectively to our customers and consistently meet their requirements.

Innovation is an important aspect of our business in all areas, helping us to deliver high quality products and services whilst allowing us to provide cost effective solutions to meet today’s needs.

Our goal is to provide best practice respiratory product solutions for patients and clinicians, offering quality, innovation and choice.

Kinseed is a specialist Software Development and Cloud Platform IT consultancy headquartered in Uxbridge, UK, which focuses on helping clients address a specific challenge through modern, disruptive and sustainable solutions. We work across organisations in heavily regulated and governed markets. including healthcare, education, financial services – focusing on delivering IT projects within strict operational and regulatory frameworks.

Kinseed is proud to be working with some of the world’s leading organisations to help transform their digital workplaces, make the most of cloud services, and develop cutting-edge technical solutions. As one example of this, Kinseed’s ground-breaking product “SwiftCare Suite” has been deployed in 6 of the top NHS healthcare trusts including Great Ormond Street Children's Hospital, Manchester University Hospital, Birmingham Children's Hospital in the UK in just under 2 years of being in the market.

kinseed.com/

Mela Solutions is a medical software company that supplies departmental solutions for clinical research and audit. With 20 years’ experience, we offer first class applications, services and value for money.

The company’s product range includes a variety of solutions for specialist teams including Paediatric ECMO, PICU, Outreach and Pain services.

Enabling users to validate and audit their data is key to our strategy. Our systems are easy to query and provide excellent analysis and reporting functionality, from a simple summary to more complex reports.

As part of the system implementation our professional services team can also help you tailor the systems to your department’s exact needs.

www.mela.co.uk

The Cardiac Center at Children’s Hospital of Philadelphia (CHOP) has one of the largest and most accomplished teams of pediatric cardiac experts in the world. We partner with physician colleagues from across the country and the world to care for patients from before birth through adulthood. At CHOP, some of the world’s leading experts are transforming the future for children with congenital heart disease by pioneering breakthroughs in treatment that will improve the lives of patients now-and for generations to come. 

https://www.chop.edu/centers-programs/cardiac-center